SG10201913200XA - Crystalline form of lorlatinib free base - Google Patents
Crystalline form of lorlatinib free baseInfo
- Publication number
- SG10201913200XA SG10201913200XA SG10201913200XA SG10201913200XA SG10201913200XA SG 10201913200X A SG10201913200X A SG 10201913200XA SG 10201913200X A SG10201913200X A SG 10201913200XA SG 10201913200X A SG10201913200X A SG 10201913200XA SG 10201913200X A SG10201913200X A SG 10201913200XA
- Authority
- SG
- Singapore
- Prior art keywords
- free base
- crystalline form
- lorlatinib free
- lorlatinib
- crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199418P | 2015-07-31 | 2015-07-31 | |
| US201662352349P | 2016-06-20 | 2016-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913200XA true SG10201913200XA (en) | 2020-03-30 |
Family
ID=56686850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913200XA SG10201913200XA (en) | 2015-07-31 | 2016-07-27 | Crystalline form of lorlatinib free base |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10420749B2 (en) |
| EP (2) | EP3798222B1 (en) |
| JP (1) | JP6218253B2 (en) |
| KR (1) | KR102088188B1 (en) |
| CN (3) | CN116063323A (en) |
| AU (1) | AU2016304420B2 (en) |
| BR (1) | BR112017028604A2 (en) |
| CA (1) | CA2937257C (en) |
| CY (1) | CY1123689T1 (en) |
| DK (2) | DK3798222T3 (en) |
| ES (1) | ES2842302T3 (en) |
| FI (1) | FI3798222T3 (en) |
| HK (1) | HK1252845A1 (en) |
| HU (1) | HUE052790T2 (en) |
| MX (2) | MX2018001324A (en) |
| PL (2) | PL3328867T3 (en) |
| PT (2) | PT3328867T (en) |
| RU (1) | RU2018101363A (en) |
| SG (1) | SG10201913200XA (en) |
| SI (2) | SI3798222T1 (en) |
| TW (1) | TWI616449B (en) |
| WO (1) | WO2017021823A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017049383A1 (en) | 2015-09-24 | 2017-03-30 | Cyclenium Pharma Inc. | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same |
| JP2019510774A (en) | 2016-04-08 | 2019-04-18 | ファイザー・インク | Crystalline form of lorlatinib maleate |
| EP3642399A4 (en) * | 2017-06-22 | 2020-10-14 | Cyclenium Pharma Inc. | Libraries of pyridine-containing macrocyclic compounds and methods of making and using the same |
| FI3694863T3 (en) * | 2017-10-10 | 2023-08-18 | Pfizer | Crystalline form of lorlatinib free base hydrate |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| US20210163498A1 (en) | 2018-04-23 | 2021-06-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN109232607A (en) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | Laura replaces the synthetic method of Buddhist nun |
| WO2020148635A1 (en) * | 2019-01-17 | 2020-07-23 | Pfizer Inc. | Crystalline form of a cdk inhibitor |
| US20220289764A1 (en) * | 2019-07-18 | 2022-09-15 | Pliva Hrvatska D.O.O. | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN110483551B (en) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | Crystals of Laratinib free base |
| CN110530998A (en) * | 2019-09-16 | 2019-12-03 | 山东省药学科学院 | A kind of Laura is for Buddhist nun and containing Laura for the detection method in relation to substance in the preparation of Buddhist nun |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (en) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | Preparation method of Laolatinib |
| TW202146017A (en) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013525476A (en) | 2010-05-04 | 2013-06-20 | ファイザー・インク | Heterocyclic derivatives as ALK inhibitors |
| JP5808818B2 (en) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | Novel salt and polymorphic forms of afatinib |
| SI2822953T1 (en) * | 2012-03-06 | 2017-04-26 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| CA2916605C (en) * | 2013-06-28 | 2018-04-24 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| CN104513253A (en) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | Macrocyclic compounds for the treatment of proliferative diseases |
| JP2019510774A (en) | 2016-04-08 | 2019-04-18 | ファイザー・インク | Crystalline form of lorlatinib maleate |
| FI3694863T3 (en) | 2017-10-10 | 2023-08-18 | Pfizer | Crystalline form of lorlatinib free base hydrate |
-
2016
- 2016-07-27 SI SI201631780T patent/SI3798222T1/en unknown
- 2016-07-27 JP JP2016146928A patent/JP6218253B2/en active Active
- 2016-07-27 DK DK20202336.2T patent/DK3798222T3/en active
- 2016-07-27 MX MX2018001324A patent/MX2018001324A/en unknown
- 2016-07-27 US US15/743,894 patent/US10420749B2/en active Active
- 2016-07-27 ES ES16751665T patent/ES2842302T3/en active Active
- 2016-07-27 EP EP20202336.2A patent/EP3798222B1/en active Active
- 2016-07-27 PT PT167516657T patent/PT3328867T/en unknown
- 2016-07-27 CN CN202310214099.4A patent/CN116063323A/en active Pending
- 2016-07-27 CN CN201680042321.5A patent/CN107849060A/en active Pending
- 2016-07-27 BR BR112017028604A patent/BR112017028604A2/en not_active Application Discontinuation
- 2016-07-27 CA CA2937257A patent/CA2937257C/en active Active
- 2016-07-27 AU AU2016304420A patent/AU2016304420B2/en active Active
- 2016-07-27 MX MX2021002220A patent/MX2021002220A/en unknown
- 2016-07-27 PL PL16751665T patent/PL3328867T3/en unknown
- 2016-07-27 SG SG10201913200XA patent/SG10201913200XA/en unknown
- 2016-07-27 HU HUE16751665A patent/HUE052790T2/en unknown
- 2016-07-27 SI SI201631027T patent/SI3328867T1/en unknown
- 2016-07-27 FI FIEP20202336.2T patent/FI3798222T3/en active
- 2016-07-27 PL PL20202336.2T patent/PL3798222T3/en unknown
- 2016-07-27 TW TW105123769A patent/TWI616449B/en active
- 2016-07-27 RU RU2018101363A patent/RU2018101363A/en unknown
- 2016-07-27 WO PCT/IB2016/054483 patent/WO2017021823A1/en active Application Filing
- 2016-07-27 PT PT202023362T patent/PT3798222T/en unknown
- 2016-07-27 DK DK16751665.7T patent/DK3328867T3/en active
- 2016-07-27 KR KR1020187002904A patent/KR102088188B1/en active IP Right Grant
- 2016-07-27 EP EP16751665.7A patent/EP3328867B9/en active Active
- 2016-07-27 CN CN202310197825.6A patent/CN116063322A/en active Pending
-
2018
- 2018-09-21 HK HK18112176.1A patent/HK1252845A1/en unknown
-
2019
- 2019-08-08 US US16/535,747 patent/US11020376B2/en active Active
-
2020
- 2020-12-30 CY CY20201101227T patent/CY1123689T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288519A (en) | Inhibitors of ret | |
| HK1252845A1 (en) | Crystalline form of lorlatinib free base | |
| SG11201706729SA (en) | Derivatives of sobetirome | |
| IL257026A (en) | Solid state forms of eluxadoline | |
| SI3380554T1 (en) | Crystalline forms of per-chloro-gamma-cyclodextrines | |
| HK1244274A1 (en) | Crystalline forms of c21h22ci2n4o2 | |
| HK1250719A1 (en) | Synthesis of desosamines | |
| ZA201706282B (en) | Solid forms of menaquinols | |
| PL3532457T3 (en) | Crystalline forms of hydroxynorketamine | |
| IL253479A0 (en) | Crystalline forms of efinaconazole | |
| PT3113773T (en) | Crystalline forms of grapiprant | |
| IL265445A (en) | Crystalline forms | |
| IL270961A (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
| HK1255148A1 (en) | Crystalline forms | |
| GB201518589D0 (en) | Crystalline form of tetraacetylethylenediamine | |
| HUP1500506A2 (en) | Salts of palbociclib | |
| IL270937A (en) | Crystalline forms of seletalisib | |
| IL261795A (en) | Crystalline form | |
| GB201502834D0 (en) | Composition of objects | |
| HUP1400294A2 (en) | Novel application of clopidogrel |